These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 28369619)

  • 1. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
    Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
    Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis.
    Andrews FH; Singh AR; Joshi S; Smith CA; Morales GA; Garlich JR; Durden DL; Kutateladze TG
    Proc Natl Acad Sci U S A; 2017 Feb; 114(7):E1072-E1080. PubMed ID: 28137841
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
    Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT
    Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
    Roca MS; Moccia T; Iannelli F; Testa C; Vitagliano C; Minopoli M; Camerlingo R; De Riso G; De Cecio R; Bruzzese F; Conte M; Altucci L; Di Gennaro E; Avallone A; Leone A; Budillon A
    J Exp Clin Cancer Res; 2022 Mar; 41(1):83. PubMed ID: 35241126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
    Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
    Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
    Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
    BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
    Ali A; Shafarin J; Unnikannan H; Al-Jabi N; Jabal RA; Bajbouj K; Muhammad JS; Hamad M
    Int J Biol Sci; 2021; 17(15):4474-4492. PubMed ID: 34803511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.
    Sahai V; Kumar K; Knab LM; Chow CR; Raza SS; Bentrem DJ; Ebine K; Munshi HG
    Mol Cancer Ther; 2014 Jul; 13(7):1907-17. PubMed ID: 24807963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.
    Sureban SM; May R; Weygant N; Qu D; Chandrakesan P; Bannerman-Menson E; Ali N; Pantazis P; Westphalen CB; Wang TC; Houchen CW
    Cancer Lett; 2014 Aug; 351(1):151-61. PubMed ID: 24880079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
    Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
    Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.
    Mody HR; Hung SW; AlSaggar M; Griffin J; Govindarajan R
    Mol Cancer Res; 2016 Nov; 14(11):1124-1135. PubMed ID: 27624777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
    Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
    Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
    Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone deacetylases in pancreatic ductal adenocarcinoma.
    Schneider G; Krämer OH; Fritsche P; Schüler S; Schmid RM; Saur D
    J Cell Mol Med; 2010 Jun; 14(6A):1255-63. PubMed ID: 19929947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
    Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
    Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.